|
ASX - By Stock
|
ATX |
Re:
Ann: ADDITIONAL RESPONSES IN ACCENT PANCREATIC CANCER TRIAL
|
|
leveller
|
43 |
12K |
4 |
30/11/25 |
| 30/11/25 |
ASX - By Stock
|
43
|
12K
|
4
|
|
|
ASX - By Stock
|
DAL |
Re:
Ann: Dalaroo to Acquire Advanced Gold Project in Cote d Ivoire
|
|
leveller
|
15 |
2.7K |
1 |
28/11/25 |
| 28/11/25 |
ASX - By Stock
|
15
|
2.7K
|
1
|
|
|
ASX - By Stock
|
ATX |
Re:
Ann: ADDITIONAL RESPONSES IN ACCENT PANCREATIC CANCER TRIAL
|
|
leveller
|
43 |
12K |
1 |
28/11/25 |
| 28/11/25 |
ASX - By Stock
|
43
|
12K
|
1
|
|
|
ASX - By Stock
|
ATX |
Re:
Ann: Positive Response from US FDA to Amplia's Type D Meeting
|
|
leveller
|
21 |
5.6K |
2 |
27/11/25 |
| 27/11/25 |
ASX - By Stock
|
21
|
5.6K
|
2
|
|
|
ASX - By Stock
|
BMR |
Re:
Ann: Change of Director's Interest Notice
|
|
leveller
|
3 |
549 |
1 |
26/11/25 |
| 26/11/25 |
ASX - By Stock
|
3
|
549
|
1
|
|
|
ASX - By Stock
|
DXB |
Re:
Ann: Chair Address and AGM Presentation
|
|
leveller
|
103 |
23K |
5 |
22/11/25 |
| 22/11/25 |
ASX - By Stock
|
103
|
23K
|
5
|
|
|
ASX - By Stock
|
CHM |
Re:
Another massive CDH17 licensing deal
|
|
leveller
|
24 |
4.7K |
5 |
20/11/25 |
| 20/11/25 |
ASX - By Stock
|
24
|
4.7K
|
5
|
|
|
ASX - By Stock
|
ATX |
Re:
Ann: Positive Response from US FDA to Amplia's Type D Meeting
|
|
leveller
|
21 |
5.6K |
4 |
20/11/25 |
| 20/11/25 |
ASX - By Stock
|
21
|
5.6K
|
4
|
|
|
ASX - By Stock
|
BMR |
Re:
Ann: Annual General Meeting Presentation
|
|
leveller
|
1 |
319 |
0 |
20/11/25 |
| 20/11/25 |
ASX - By Stock
|
1
|
319
|
0
|
|
|
ASX - By Stock
|
DXB |
Re:
Ann: Chair Address and AGM Presentation
|
|
leveller
|
103 |
23K |
2 |
19/11/25 |
| 19/11/25 |
ASX - By Stock
|
103
|
23K
|
2
|
|
|
ASX - By Stock
|
CYC |
Re:
Ann: Cyclopharm Bell Potter Healthcare Conference Presentation
|
|
leveller
|
48 |
7.9K |
2 |
19/11/25 |
| 19/11/25 |
ASX - By Stock
|
48
|
7.9K
|
2
|
|
|
ASX - By Stock
|
BMM |
Re:
Ann: Outstanding CSAMT Results at Bayan Springs South
|
|
leveller
|
2 |
936 |
1 |
17/11/25 |
| 17/11/25 |
ASX - By Stock
|
2
|
936
|
1
|
|
|
ASX - By Stock
|
DUG |
Re:
Ann: Application for quotation of securities - DUG
|
|
leveller
|
7 |
1.3K |
0 |
15/11/25 |
| 15/11/25 |
ASX - By Stock
|
7
|
1.3K
|
0
|
|
|
ASX - By Stock
|
BMR |
Re:
Ann: Maniopota EM identifies significant polymetallic targets
|
|
leveller
|
12 |
3.5K |
2 |
15/11/25 |
| 15/11/25 |
ASX - By Stock
|
12
|
3.5K
|
2
|
|
|
ASX - By Stock
|
CYC |
Re:
Ann: Cyclopharm Completes Sale of Cyclotron Asset
|
|
leveller
|
4 |
913 |
0 |
12/11/25 |
| 12/11/25 |
ASX - By Stock
|
4
|
913
|
0
|
|
|
ASX - By Stock
|
BMR |
Re:
Ann: Torpys drilling discovers massive sulphide Pb-Zn-Ag system
|
|
leveller
|
5 |
1.4K |
0 |
12/11/25 |
| 12/11/25 |
ASX - By Stock
|
5
|
1.4K
|
0
|
|
|
ASX - By Stock
|
ATX |
Re:
Ann: Amplia Commences Trading on U.S. OTCQB Venture Market
|
|
leveller
|
17 |
4.7K |
3 |
06/11/25 |
| 06/11/25 |
ASX - By Stock
|
17
|
4.7K
|
3
|
|
|
ASX - By Stock
|
ATX |
Re:
Ann: Amplia Commences Trading on U.S. OTCQB Venture Market
|
|
leveller
|
17 |
4.7K |
2 |
06/11/25 |
| 06/11/25 |
ASX - By Stock
|
17
|
4.7K
|
2
|
|
|
ASX - By Stock
|
DAL |
Re:
Ann: Quarterly Activity and Cashflow Report
|
|
leveller
|
2 |
601 |
2 |
05/11/25 |
| 05/11/25 |
ASX - By Stock
|
2
|
601
|
2
|
|
|
ASX - By Stock
|
BMR |
Re:
Ann: Drilling of Seventy Mile Mount breccia pipe target commences
|
|
leveller
|
2 |
540 |
2 |
05/11/25 |
| 05/11/25 |
ASX - By Stock
|
2
|
540
|
2
|
|
|
ASX - By Stock
|
BMR |
Re:
Ann: Quarterly Activities/Appendix 5B Cash Flow Report
|
|
leveller
|
1 |
361 |
1 |
31/10/25 |
| 31/10/25 |
ASX - By Stock
|
1
|
361
|
1
|
|
|
ASX - By Stock
|
EYE |
Re:
Ann: Quarterly Activities/Appendix 4C Cash Flow Report
|
|
leveller
|
51 |
9.5K |
2 |
31/10/25 |
| 31/10/25 |
ASX - By Stock
|
51
|
9.5K
|
2
|
|
|
ASX - By Stock
|
ATX |
Re:
Ann: Quarterly Activities/Appendix 4C Cash Flow Report
|
|
leveller
|
4 |
1.3K |
8 |
30/10/25 |
| 30/10/25 |
ASX - By Stock
|
4
|
1.3K
|
8
|
|
|
ASX - By Stock
|
CYC |
Re:
Ann: Webinar - Cyclopharm Business Update
|
|
leveller
|
69 |
24K |
0 |
27/10/25 |
| 27/10/25 |
ASX - By Stock
|
69
|
24K
|
0
|
|
|
ASX - By Stock
|
BMM |
Re:
Ann: Strategic and Technical Advancements at Desert Star Projects
|
|
leveller
|
48 |
7.3K |
1 |
24/10/25 |
| 24/10/25 |
ASX - By Stock
|
48
|
7.3K
|
1
|
|
|
ASX - By Stock
|
DAL |
Re:
'Major step forward': Dalaroo Metals up +26% after buying into Côte d'Ivoire with 4 gold permits
|
|
leveller
|
2 |
366 |
1 |
15/10/25 |
| 15/10/25 |
ASX - By Stock
|
2
|
366
|
1
|
|
|
ASX - By Stock
|
BMR |
Re:
Ann: Maniopota EM identifies significant polymetallic targets
|
|
leveller
|
12 |
3.5K |
1 |
13/10/25 |
| 13/10/25 |
ASX - By Stock
|
12
|
3.5K
|
1
|
|
|
ASX - By Stock
|
CYC |
Re:
Ann: Legal Proceedings
|
|
leveller
|
16 |
4.7K |
3 |
13/10/25 |
| 13/10/25 |
ASX - By Stock
|
16
|
4.7K
|
3
|
|
|
ASX - By Stock
|
MVP |
Re:
Ann: 2025 Annual General Meeting Webcast recording
|
|
leveller
|
1 |
379 |
1 |
13/10/25 |
| 13/10/25 |
ASX - By Stock
|
1
|
379
|
1
|
|
|
ASX - By Stock
|
ATX |
Re:
Ann: ADDITIONAL RESPONSES IN ACCENT PANCREATIC CANCER TRIAL
|
|
leveller
|
43 |
12K |
2 |
10/10/25 |
| 10/10/25 |
ASX - By Stock
|
43
|
12K
|
2
|
|
|
ASX - By Stock
|
CYC |
Re:
Ann: Legal Proceedings
|
|
leveller
|
16 |
4.7K |
0 |
07/10/25 |
| 07/10/25 |
ASX - By Stock
|
16
|
4.7K
|
0
|
|
|
ASX - By Stock
|
ATX |
Re:
Ann: Patent Allowance for Key Narmafotinib Patent in US
|
|
leveller
|
18 |
5.3K |
0 |
03/10/25 |
| 03/10/25 |
ASX - By Stock
|
18
|
5.3K
|
0
|
|
|
ASX - By Stock
|
ATX |
Re:
ATX - Media thread
|
|
leveller
|
98 |
42K |
1 |
22/09/25 |
| 22/09/25 |
ASX - By Stock
|
98
|
42K
|
1
|
|
|
ASX - By Stock
|
ATX |
Re:
Life Science Virtual Investor Conferences
|
|
leveller
|
7 |
1.9K |
17 |
20/09/25 |
| 20/09/25 |
ASX - By Stock
|
7
|
1.9K
|
17
|
|
|
ASX - By Stock
|
SMN |
Re:
Testia NDT
|
|
leveller
|
19 |
3.1K |
3 |
17/09/25 |
| 17/09/25 |
ASX - By Stock
|
19
|
3.1K
|
3
|
|
|
ASX - By Stock
|
SMN |
Re:
Testia NDT
|
|
leveller
|
19 |
3.1K |
1 |
17/09/25 |
| 17/09/25 |
ASX - By Stock
|
19
|
3.1K
|
1
|
|
|
ASX - By Stock
|
CHM |
Re:
Ann: Webinar - CHM CDH17 deep dive with Professor Jennifer Eads
|
|
leveller
|
108 |
24K |
9 |
11/09/25 |
| 11/09/25 |
ASX - By Stock
|
108
|
24K
|
9
|
|
|
ASX - By Stock
|
MVP |
Re:
Ann: 2025 Annual Report
|
|
leveller
|
11 |
2.5K |
0 |
08/09/25 |
| 08/09/25 |
ASX - By Stock
|
11
|
2.5K
|
0
|
|
|
Charts
|
SMN |
Re:
SMN - Chart
|
|
leveller
|
4.3K |
1.7M |
3 |
05/09/25 |
| 05/09/25 |
Charts
|
4.3K
|
1.7M
|
3
|
|
|
Charts
|
SMN |
Re:
SMN - Chart
|
|
leveller
|
4.3K |
1.7M |
10 |
04/09/25 |
| 04/09/25 |
Charts
|
4.3K
|
1.7M
|
10
|
|
|
Charts
|
SMN |
Re:
SMN - Chart
|
|
leveller
|
4.3K |
1.7M |
0 |
04/09/25 |
| 04/09/25 |
Charts
|
4.3K
|
1.7M
|
0
|
|
|
ASX - By Stock
|
BMR |
Re:
Ann: Maniopota EM identifies significant polymetallic targets
|
|
leveller
|
12 |
3.5K |
2 |
02/09/25 |
| 02/09/25 |
ASX - By Stock
|
12
|
3.5K
|
2
|
|
|
ASX - By Stock
|
ATX |
Re:
Ann: Managing Director's Presentation to AGM
|
|
leveller
|
69 |
18K |
2 |
01/09/25 |
| 01/09/25 |
ASX - By Stock
|
69
|
18K
|
2
|
|
|
ASX - By Stock
|
ATX |
Re:
Ann: Managing Director's Presentation to AGM
|
|
leveller
|
69 |
18K |
1 |
28/08/25 |
| 28/08/25 |
ASX - By Stock
|
69
|
18K
|
1
|
|
|
ASX - By Stock
|
EYE |
Re:
Ann: Appendix 4E and Annual Report
|
|
leveller
|
21 |
5.3K |
4 |
27/08/25 |
| 27/08/25 |
ASX - By Stock
|
21
|
5.3K
|
4
|
|
|
ASX - By Stock
|
CYC |
Re:
Ann: CYC 1H2025 Results Summary
|
|
leveller
|
2 |
576 |
1 |
27/08/25 |
| 27/08/25 |
ASX - By Stock
|
2
|
576
|
1
|
|
|
ASX - By Stock
|
ATX |
Re:
Ann: Managing Director's Presentation to AGM
|
|
leveller
|
69 |
18K |
2 |
27/08/25 |
| 27/08/25 |
ASX - By Stock
|
69
|
18K
|
2
|
|
|
ASX - By Stock
|
SMN |
Re:
Ann: Strategic Leadership Appointment - Interim AEM CEO
|
|
leveller
|
56 |
11K |
3 |
26/08/25 |
| 26/08/25 |
ASX - By Stock
|
56
|
11K
|
3
|
|
|
ASX - By Stock
|
MVP |
Re:
Another Positive Study
|
|
leveller
|
256 |
142K |
2 |
26/08/25 |
| 26/08/25 |
ASX - By Stock
|
256
|
142K
|
2
|
|
|
ASX - By Stock
|
DUG |
Re:
Ann: FY25 Financial Results
|
|
leveller
|
6 |
2.7K |
7 |
22/08/25 |
| 22/08/25 |
ASX - By Stock
|
6
|
2.7K
|
7
|
|